市场见解

Experts rate these 2 ASX healthcare shares as buys in 2022

Volpara is one of the ASX healthcare shares that experts like for 2022.
The post Experts rate these 2 ASX healthcare shares as buys in 2022 appeared first on The Motley Fool Australia. –

Some ASX healthcare shares have been rated as buys for 2022 by experts.

Healthcare companies have the potential of producing both growth and defensive earnings. People don’t choose when they get sick, and health is very important to most people (and use services).

There are plenty of different sectors within healthcare, including private health insurance, hospitals, medical devices and products, diagnostic and software.

Experts rate these two ASX healthcare shares as buys for the year ahead:

Volpara Health Technologies Ltd (ASX: VHT)

Volpara is currently rated as a buy by the broker Morgans, with a price target of $1.87. That suggests that the business could rise by around 80% over the next year (if the broker is right about how the market treats the business).

A significant part of Volpara’s advantage is the ability of the company to analyse millions of images that will help the company find breast cancer, perhaps even before it has developed.

The company recently released its FY22 first half result, which showed that subscription revenue went up 35% to NZ$11.8 million (up 42% in constant currency terms).

Its market share continues to grow. At least one of Volpara’s products are now used on approximately 34% of women in the US. That was an increase from 27% a year ago.

The company has a very high gross profit margin. It was 91.4% in the last result. This is very high for a company on the ASX.

Volpara has made a number of partnerships that has positioned the business for lung expansion. It has made an initial investment in RevealDx, a lung AI company based in Seattle and it has signed a collaboration agreement with Riverain Technologies. Management thinks that lung is a large opportunity too.

Sonic Healthcare Ltd (ASX: SHL)

Sonic is an essential healthcare services business which provides a number of pathology services, as well as imaging. It generates revenue from across several countries including the USA, Germany, Australia, New Zealand, the UK, Ireland, Switzerland and Belgium.

COVID-19 has been a boost for the ASX healthcare share’s earnings and the base business revenue continues to grow by mid-single digits. Total FY21 revenue increased 28% and net profit jumped 149%. It benefited from being able to utilise existing infrastructure to generate operating leverage.

FY22 has seen continuing growth. In the first four months of FY22, revenue increased 5% and earnings before interest, tax, depreciation and amortisation (EBITDA) rose by 16%.

Morgans rates Sonic Healthcare as a buy, with a price target of $47.05. It thinks that Sonic’s profit margins continue to grow.

The ASX healthcare share has also announced recent strategic moves.

It has signed an agreement to form a joint venture company with Harrison.ai, an Australian healthcare AI company, to co-develop and commercialise effective and accurate clinical AI solutions in pathology. It has also taken a “significant strategic shareholding” in Harrison.ai.

The business has also revealed it has bought ProPath, an anatomical pathology (AP) company based in Dallas, Texas. Its annual revenue generation is around US$110 million, serving more than 20 hospital groups across 45 states. This acquisition was deemed as a very significant additional step in developing its AP and clinical laboratory operations in the US.

The post Experts rate these 2 ASX healthcare shares as buys in 2022 appeared first on The Motley Fool Australia.

Should you invest $1,000 in Sonic Healthcare right now?

Before you consider Sonic Healthcare, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Sonic Healthcare wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

ASX 200 (ASX:XJO) midday update: BNPL shares sold off, Corporate Travel returns

Sonic Healthcare (ASX:SHL) share price struggles despite US acquisition

What’s the outlook for ASX healthcare shares in 2022?

2 healthcare ASX shares that Morgans loves right now

2 fast growth ASX shares that could be buys in December 2021

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended VOLPARA FPO NZ. The Motley Fool Australia owns and has recommended VOLPARA FPO NZ. The Motley Fool Australia has recommended Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

随时随地,交易世界!

移动APP平台,拥有 12 个市场的 50,000 多种全球上市证券(全球市值超过 70%),直接在您的 Android 或 iOS 设备上即可操作。

与独有的交易理念和投资分析工具相结合,帮助您在我们 12 个全球市场中的几乎所有金融工具上找到可操作的见解,从而帮助您优化交易策略。

推荐给您的朋友

向您的朋友推荐Monex并赠予他们免费使用我们交易工具的机会

我们尊重您的隐私,只会向您的朋友发送一封邮件 

与您的朋友分享

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!